CCCC — C4 Therapeutics Share Price
0.000.00%
Last trade - 00:00- $123.55m
- -$121.35m
- $35.58m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.57 | ||
| Price to Tang. Book | 0.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.29% | ||
| Return on Equity | -45.58% | ||
| Operating Margin | -336.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 33.2 | 45.78 | 31.1 | 20.76 | 35.58 | 24.18 | 32.96 | 10.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Directors
- Marc Cohen CHM (57)
- Andrew Hirsch PRE (50)
- Lauren White CFO (42)
- Stewart Fisher CSO (54)
- Adam Crystal OTH (44)
- Jolie Siegel SEC (44)
- Kenneth Anderson IND (69)
- Alain Cohen IND (54)
- Bruce Downey IND (73)
- Glenn Dubin IND (64)
- Elena Prokupets IND (66)
- Malcolm Salter IND (81)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 7th, 2015
- Public Since
- October 2nd, 2020
- No. of Shareholders
- 76
- No. of Employees
- 110
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 71,007,083
- Address
- 490 Arsenal Way, Suite 120, WATERTOWN, 02472
- Web
- https://c4therapeutics.com/
- Phone
- +1 6172310700
- Contact
- Courtney Solberg
- Auditors
- KPMG
Upcoming Events for CCCC
C4 Therapeutics Inc Annual Shareholders Meeting
C4 Therapeutics Inc Annual Shareholders Meeting
Q2 2025 C4 Therapeutics Inc Earnings Release
Q3 2025 C4 Therapeutics Inc Earnings Release
Similar to CCCC
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the C4 Therapeutics share price?
As of Today at 19:44 UTC, shares in C4 Therapeutics are trading at $1.74. This share price information is delayed by 15 minutes.
How has the C4 Therapeutics share price performed this year?
Shares in C4 Therapeutics last closed at $1.74 and the price had moved by -72.94% over the past 365 days. In terms of relative price strength the C4 Therapeutics share price has underperformed the S&P500 Index by -75.6% over the past year.
What are the analyst and broker recommendations for C4 Therapeutics?
The overall consensus recommendation for C4 Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the C4 Therapeutics dividend yield?
C4 Therapeutics does not currently pay a dividend.
Does C4 Therapeutics pay a dividend?
C4 Therapeutics does not currently pay a dividend.
When does C4 Therapeutics next pay dividends?
C4 Therapeutics does not currently pay a dividend.
How do I buy C4 Therapeutics shares?
To buy shares in C4 Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of C4 Therapeutics?
As of the previous close price of $1.74, shares in C4 Therapeutics had a market capitalisation of $123.55m.
Where are C4 Therapeutics shares listed?
Here are the trading details for C4 Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CCCC
What kind of share is C4 Therapeutics?
Based on an overall assessment of its quality, value and momentum C4 Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a C4 Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in C4 Therapeutics is $16.07. That is 823.56% above the last closing price of $1.74.
Analysts covering C4 Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.85 for the next financial year.
Find out moreWhat is the trend in the C4 Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like C4 Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -68.84%.
As of the last closing price of $1.74, shares in C4 Therapeutics were trading -59.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the C4 Therapeutics PE Ratio?
The C4 Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of C4 Therapeutics?
C4 Therapeutics' management team is headed by:
- Marc Cohen - CHM
- Andrew Hirsch - PRE
- Lauren White - CFO
- Stewart Fisher - CSO
- Adam Crystal - OTH
- Jolie Siegel - SEC
- Kenneth Anderson - IND
- Alain Cohen - IND
- Bruce Downey - IND
- Glenn Dubin - IND
- Elena Prokupets - IND
- Malcolm Salter - IND